Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The kidney in type 2 diabetes therapy.

Heerspink HJ, de Zeeuw D.

Rev Diabet Stud. 2011 Fall;8(3):392-402. doi: 10.1900/RDS.2011.8.392. Epub 2011 Nov 10. Review.

2.

Albuminuria: a target for treatment of type 2 diabetic nephropathy.

de Zeeuw D.

Semin Nephrol. 2007 Mar;27(2):172-81. Review.

PMID:
17418686
3.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
5.

Antihypertensive treatment and multifactorial approach for renal protection in diabetes.

Fioretto P, Solini A.

J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S18-21. Review.

6.
7.

Treatment of microalbuminuria in patients with type 2 diabetes mellitus.

Jerums G, MacIsaac RJ.

Treat Endocrinol. 2002;1(3):163-73. Review.

PMID:
15799209
8.

Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy.

Bretzel RG.

J Diabetes Complications. 1997 Mar-Apr;11(2):112-22. Review.

PMID:
9101397
9.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
11.

Current concepts in the management of diabetic nephropathy.

Waanders F, Visser FW, Gans RO.

Neth J Med. 2013 Nov;71(9):448-58. Review.

12.

The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.

Zanella MT, Ribeiro AB.

Clin Ther. 2002 Jul;24(7):1019-34. Review.

PMID:
12182249
13.

Investigational drugs for diabetic nephropathy.

Cortinovis M, Cattaneo D, Perico N, Remuzzi G.

Expert Opin Investig Drugs. 2008 Oct;17(10):1487-500. doi: 10.1517/13543784.17.10.1487 . Review.

PMID:
18808309
14.
15.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
16.

[The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].

Ravera M, Deferrari L, Ratto E, Vettoretti S, Parodi D, Deferrari G.

Ital Heart J Suppl. 2003 Mar;4(3):210-6. Review. Italian.

PMID:
12784755
17.

What are new avenues for renal protection, in addition to RAAS inhibition?

Hagiwara S, Kantharidis P, Cooper ME.

Curr Hypertens Rep. 2012 Apr;14(2):100-10. doi: 10.1007/s11906-012-0251-1. Review.

PMID:
22298106
18.

Treatment and landmark clinical trials for renoprotection.

Ting RZ, Luk AO, Chan JC.

Contrib Nephrol. 2011;170:184-95. doi: 10.1159/000325663. Epub 2011 Jun 9. Review.

PMID:
21659771
19.

Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.

Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.

Horm Metab Res. 2005 Apr;37 Suppl 1:4-8.

PMID:
15918104
20.

Blood pressure lowering for the prevention and treatment of diabetic kidney disease.

Thomas MC, Atkins RC.

Drugs. 2006;66(17):2213-34. Review.

PMID:
17137404
Items per page

Supplemental Content

Write to the Help Desk